US 12,295,952 B2
Methods of treating heart failure with cardiac sarcomere activators
Narimon Honarpour, Thousand Oaks, CA (US); and Fady Malik, South San Francisco, CA (US)
Assigned to CYTOKINETICS, INC., South San Francisco, CA (US); and AMGEN INC., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US); and Cytokinetics, Inc., South San Francisco, CA (US)
Filed on Jan. 17, 2023, as Appl. No. 18/155,483.
Application 18/155,483 is a division of application No. 16/625,958, granted, now 11,576,910, previously published as PCT/US2018/040181, filed on Jun. 29, 2018.
Claims priority of provisional application 62/527,983, filed on Jun. 30, 2017.
Prior Publication US 2023/0149394 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61K 9/00 (2006.01); A61P 9/04 (2006.01)
CPC A61K 31/496 (2013.01) [A61K 9/0053 (2013.01); A61P 9/04 (2018.01)] 31 Claims
 
1. A method of determining a treatment regimen for a subject with heart failure (HF), comprising
(a) administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, wherein the initial dose of the CSA is about 25 mg twice daily,
(b) determining the subject's plasma concentration of the CSA at about 2 weeks after the first administration of the initial dose, and
(c) determining a treatment regimen based on the subject's plasma concentration of the CSA,
wherein the treatment regimen comprises (i) administering to the subject an initial dose of the CSA for an initial time period, wherein the initial dose of the CSA is about 25 mg twice daily; and (ii) subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA at about 2 weeks after the first administration of the initial dose,
wherein when the subject's plasma concentration of the CSA is less than a threshold concentration of 300 ng/mL, the dose subsequently administered to the subject is greater than the initial dose; and wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof.